Genmab — November 2020

[Bulder]

Tak bibob. “From the point of view of safety, the [toxicity] profile [of GEN1046] is durable, and it was very much focused on liver safety since previous agonists directed to 4-1BB had problems with this,” noted Melero.

[bibob]

Jeg hæftede mig også ved de forskellige doser.

[bibob]

And the MTD was not yet reached.

[Solsen]

Håber på nye opdaterede data i dag. De må kende resultaterne på yderligere et par måneder af forsøget.

[Sukkeralf]

Tror jeg ikke vi får - måske lidt løst mellem linierne fra Jan

[E_L]

i would not expect too much extra data, efficacy data was Sep 29, NSCLC expansian was Oct 12?

[E_L]

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications https://ashpublications.org/blood/article-abstract/136/20/2334/461276/The-JAK-STAT-pathway-regulates-CD38-on-myeloma?redirectedFrom=fulltext

[E_L]

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://www.mdpi.com/1422-0067/21/22/8553/htm

[E_L]

lol, how to make a headline that will
get people to click on your article, "Janssen combines Darzalex with COVID drug in new multiple myeloma submission" https://pharmaphorum.com/news/janssen-combines-darzalex-with-covid-drug-in-new-multiple-myeloma-submission/

[DevOp]

Seems data from the NSCLC expansion is unlikely to be presented already, but aren't they compelled to present the data either at a conference or at least one of the medical journals? And if that's the case, I guess ASH would be no good as it's only hematology - but which conference would be a good guess for results then - something in May/June?

[Bulder]

One of these https://waset.org/oncology-conferences

[Bulder]

Asco would be a good guess

[DevOp]

thx, Bulder - that's a pretty comprehensive list :-
)

[Helge_LarsenPI-redaktør]

Reminder: https://events.bizzabo.com/GenmabCMD

[Solsen]

Siden er nede. Help ....

[E_L]

nice timing:

[E_L]

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL https://clinicaltrials.gov/ct2/show/NCT04628494?term=NCT04628494&draw=2&rank=1

[E_L]

LYRA / Dara-CyBorD completed https://clinicaltrials.gov/ct2/history/NCT02951819?A=25&B=26&C=merged#StudyPageTop

[E_L]

another Dara label extension to follow shortly - Positive recommendations on extensions of indications Name of medicine Kyprolis INN carfilzomib
Marketing-authorisation holder Amgen Europe B.V. More information Kyprolis: Pending EC decision (Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone)

[Solsen]

Dejligt med live billeder